← All trials
NCT03117335
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 10, 2011
- Primary completion
- Nov 14, 2016
- Completion date
- Jan 17, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 560
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.Lead sponsor
- Tigermed Consulting Co., LtdCollaborator
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.